Arcadia Biosciences Inc   (RKDA)
Other Ticker:  
Price: $2.0299 $0.11 5.724%
Day's High: $2.19 Week Perf: 2.79 %
Day's Low: $ 1.94 30 Day Perf: -19.29 %
Volume (M): 67 52 Wk High: $ 7.30
Volume (M$): $ 136 52 Wk Avg: $3.56
Open: $1.96 52 Wk Low: $1.85

 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 1
 Employees 47
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Arcadia Biosciences Inc

We, a corporation formed in 2002, are an agricultural biotechnology trait company engaged in the development of traits that improve food, feed and fiber crops and enhance the value of the resulting agricultural products. Our customers include seed companies who incorporate these traits into their elite varieties to increase the value of a crop for farmers, as well as food and feed companies who make products that increase the choices and nutritional value of foods for consumers.

We are focused on two distinct areas of the agricultural supply chain:

Improvement of crop yield by mitigating the impacts of abiotic stresses such as drought, heat, nutrient deficiency, water scarcity, and soil salinity. These stresses are prevalent in most agricultural environments with varying degrees of severity and often have material consequences on crop production, quality, and farmer incomes. Our traits have been introgressed into several crops, including rice, wheat, and soybeans, and we have demonstrated significant yield improvements in multiple years of field testing. In addition to improving the efficiency of agricultural productions, these traits also have the potential of reducing the impact of agriculture on the environment by lowering water requirements and reducing the occurrence of excess nitrogen runoff from intensive farming.

Enhancement of the nutritional quality of crops by changing the compositional quality of oilseeds and grains. We currently produce and market the SONOVA® brand of oil containing Gamma Linolenic Acid (GLA), an omega-6 fatty acid derived from safflower. We recently received GRAS notification (generally recognized as safe) from the FDA for use of SONOVA GLA safflower oil in medical foods and nutritional beverages, which we expect will expand the market for this product. In addition, we are in late stage development of Resistant Starch (RS) wheat, a product with twice as much fiber content as conventional wheat. This and other wheat quality products in our pipeline are being developed using our non-transgenic TILLING technology platform.

Our business model is to access trait technologies that have already achieved proof of concept whether in a public research program or with commercial partners. We further develop these technologies by optimizing their function and validating their performance through intensive field trial testing in multiple crops under varying growth conditions, thereby better establishing commercial viability for resulting products. We then license our technologies to major seed and consumer product companies who perform additional testing and product development and, where needed, generate the requisite data to support regulatory submissions and approvals. License agreements with our partners may include financial and non-financial milestones. When products containing our traits are commercialized we will receive a share of the revenue. In select instances, we also work with our commercial partners to make the regulatory filings required to support commercial launch of the traits in order to increase our share of the revenue.

We use both genetically modified, or GM, and non-GM technologies to develop our traits. This approach allows us to select the most appropriate technology for development of a particular trait, crop and market. However, a key component of the development cycle of GM traits is that U.S., or in some instances, global deregulation of the trait by one or more regulatory agencies may be required. As there continues to be a significant debate about the role of GM traits in agricultural crops, we have seen this issue begin to impact some regulatory agencies which exercise control over the pace of deregulation of products, thereby allowing commercialization. We have recently experienced delays in the review of many of our high value traits principally due to inaction from these government regulatory authorities. For example, in India, where regulators have not approved field trials for testing of GM traits for the last two years, we estimate the impact to trait development and crop commercialization timelines of our license partner in India, Maharashtra Hybrid Seeds Company Ltd. (“Mahyco”), could be at least two to three year delay.

   Company Address: 5950 Sherry Lane Dallas 75225 TX
   Company Phone Number: 974-8921   Stock Exchange / Ticker: NASDAQ RKDA

Customers Net Income grew by RKDA's Customers Net Profit Margin grew to

0.46 %

8.88 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AVD   -7.17%    
CF   -3.76%    
CGA   -5.74%    
MOS   -5.58%    
SANW   -6.79%    
CVI   -5.67%    
• View Complete Report

Arcadia Biosciences Inc

Arcadia Biosciences Inc witnesses alarming increase in diminishing returns during July-September 2023 financial period

Arcadia Biosciences Inc: A Closer Look at a Falling Star
Arcadia Biosciences Inc, a leading agricultural biotechnology company, has recently reported its financial performance for the July to September 30, 2023 timeframe, and the results are far from encouraging. With a remarkable increase in losses per share and a significant decline in revenue, the company is facing some serious challenges in the market. Let's dive deeper into the numbers and understand the current situation at Arcadia Biosciences Inc.
Starting with the financials, the loss per share for the reported period stands at $-1.89, a stark contrast to the previous year's figure of $-0.12. This substantial increase in losses per share points towards a troubled financial performance. Additionally, the earnings per share (EPS) also witnessed a decline, falling from $0.61 per share in the preceding reporting period to $-1.89 per share.

Arcadia Biosciences Inc

Arcadia Biosciences Inc. Faces Uphill Battle with Plummeting Revenue in Q2 2023

Arcadia Biosciences Inc. (RKDA) is a company in grave trouble as its financials indicate a deteriorating performance across various key metrics. Despite a slight improvement in earnings per share (EPS) and bottom-line profitability, the alarming decline in revenue, stockpiles, and accounts receivable, coupled with a significant drop in stock value over the past seven days, suggest a bleak future for the company.
Financial Performance:
For the fiscal period ending June 30, 2023, RKDA reported a meager EPS of $0.61 per share. While this demonstrates some improvement compared to a loss of $0.17 per share a year ago, the historical perspective shows RKDA struggling to generate consistent positive earnings. Furthermore, the income per share turned positive after a dismal performance in the preceding financial quarter, but remained significantly lower than the industry average at $-10.86 per share.

Arcadia Biosciences Inc

RKDA's Losses Deepen in Q1 2023, Steepest Drop in ROE at -91.23%

Arcadia Biosciences Inc. experiences $-20 million net loss in Q1 2023; ROE plunges by -91.23%
In the first quarter of 2023, Arcadia Biosciences Inc., a biotechnology company focused on developing agricultural products, reported a cumulative net loss of $-20 million. This negative figure resulted in a return on equity (ROE) of -91.23%, which is a noticeable decline from the previous quarter.
This downturn has seen Arcadia Biosciences fall in rankings compared to other agricultural production companies with 28 other companies having a higher ROE than Arcadia Biosciences.


Arcadia Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com